MX2019014667A - Tratamiento de trastornos cutaneos. - Google Patents

Tratamiento de trastornos cutaneos.

Info

Publication number
MX2019014667A
MX2019014667A MX2019014667A MX2019014667A MX2019014667A MX 2019014667 A MX2019014667 A MX 2019014667A MX 2019014667 A MX2019014667 A MX 2019014667A MX 2019014667 A MX2019014667 A MX 2019014667A MX 2019014667 A MX2019014667 A MX 2019014667A
Authority
MX
Mexico
Prior art keywords
skin
cantharidin
treatment
lesion
treating
Prior art date
Application number
MX2019014667A
Other languages
English (en)
Inventor
Welgus Howard
Gene Davidson Matthew
Michael Rieger Jayson
Original Assignee
Verrica Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verrica Pharmaceuticals Inc filed Critical Verrica Pharmaceuticals Inc
Publication of MX2019014667A publication Critical patent/MX2019014667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar una o más lesiones cutáneas usando cantaridina, así como composiciones, regímenes de tratamiento, kits, dispositivos y sistemas asociados; un método para tratar a un sujeto que tiene una o más lesiones cutáneas puede implicar la administración de una composición que comprende cantaridina a una o más lesiones cutáneas; el método puede permitir el tratamiento eficaz de la(s) lesión(es) cutánea(s) con efectos secundarios adversos mínimos o nulos (por ejemplo, efectos secundarios adversos graves, daño permanente del tejido dérmico, cicatrización, ampollas excesivas en la piel que rodea la lesión, cantaridina plasmática elevada concentración, exposición sistémica a la cantaridina); la eficacia y/o seguridad del tratamiento puede deberse a ciertas características de la composición y/o exposición prolongada de la(s) lesión(es) de la piel a la cantaridina; los métodos descritos en este documento pueden usarse para una amplia variedad de trastornos cutáneos, incluidos trastornos de la piel que afectan principalmente a la epidermis de la piel.
MX2019014667A 2017-06-06 2018-06-06 Tratamiento de trastornos cutaneos. MX2019014667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516061P 2017-06-06 2017-06-06
PCT/US2018/036353 WO2018226894A1 (en) 2017-06-06 2018-06-06 Treatment of cutaneous disorders

Publications (1)

Publication Number Publication Date
MX2019014667A true MX2019014667A (es) 2020-02-07

Family

ID=64565991

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014667A MX2019014667A (es) 2017-06-06 2018-06-06 Tratamiento de trastornos cutaneos.
MX2022008203A MX2022008203A (es) 2017-06-06 2019-12-05 Tratamiento de trastornos cutaneos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008203A MX2022008203A (es) 2017-06-06 2019-12-05 Tratamiento de trastornos cutaneos.

Country Status (10)

Country Link
US (2) US11147790B2 (es)
EP (1) EP3634370A4 (es)
JP (2) JP7280870B2 (es)
KR (1) KR20200050941A (es)
CN (1) CN111278414A (es)
AU (2) AU2018281313B2 (es)
CA (1) CA3065151A1 (es)
IL (2) IL270900B1 (es)
MX (2) MX2019014667A (es)
WO (1) WO2018226894A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308690B2 (en) 2013-08-21 2019-07-18 Verrica Pharmaceuticals, Inc. Compositions, methods and systems for the treatment of cutaneous disorders
US11168091B2 (en) 2015-01-20 2021-11-09 Verrica Pharmaceuticals Inc. Quantification and preparation of pharmaceutical grade cantharidin
IL270900B1 (en) 2017-06-06 2024-08-01 Verrica Pharmaceuticals Inc Treatment of skin disorders
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US600556A (en) 1898-03-15 Pyroxylin compound
AU512465B2 (en) 1977-01-05 1980-10-09 Basf Aktiengesellschaft Manufacture of 3-halosulfonylthiophene-carboxylic acid derivatives
US4148874A (en) 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
US4298752A (en) 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JP3117502B2 (ja) 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
JPH05255367A (ja) 1992-02-28 1993-10-05 Jitsuei O カンタリジン誘導体組成物の製造法及びそれを含む抗ウイルス剤
US5445462A (en) 1993-08-03 1995-08-29 Medi-Flex Hospital Products, Inc. Liquid applicator
WO1995005156A1 (en) 1993-08-17 1995-02-23 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US5590780A (en) 1995-06-22 1997-01-07 Wheaton Holding, Inc. Unit dose assembly
FR2754175B1 (fr) 1996-10-07 1999-07-02 Oreal Utilisation d'un organopolysiloxane de nature elastomerique associe a une phase organique dans un produit de demaquillage des ongles
US6030633A (en) 1998-05-18 2000-02-29 West Agro, Inc. Film-forming compositions for protecting animal skin
JPH11335303A (ja) 1998-05-26 1999-12-07 Lion Corp 苦味増強方法及び皮膚外用剤
US6066124A (en) 1998-11-24 2000-05-23 Caillouette; James C. Control of treatment fluid application to tissue
USD436661S1 (en) 1999-05-20 2001-01-23 Melvin P Berry Suppository applicator
US6337076B1 (en) 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
FR2808662B1 (fr) 2000-05-09 2002-12-20 Delviel Systeme d'application d'une composition sur un element de surface
US6899897B2 (en) 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
US6547467B2 (en) 2001-08-29 2003-04-15 Closure Medical Corporation Microapplicators, delivery systems and methods for adhesives and sealants
US6673031B2 (en) 2001-09-25 2004-01-06 Phillip Mark Liquid applicator
JP4739621B2 (ja) 2001-12-25 2011-08-03 株式会社ダイヘン 消耗電極式アーク溶接装置
JP2004059446A (ja) 2002-07-25 2004-02-26 Mitsui Chemicals Inc 脂環式化合物及びその製造方法
US20040162533A1 (en) 2003-02-06 2004-08-19 Alley Kenneth A. Applicator device
JP2006521887A (ja) 2003-03-31 2006-09-28 ニック ジェイ マニーシス 多数回投与液体分配組立体
US20040242770A1 (en) 2003-04-16 2004-12-02 Feldstein Mikhail M. Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
US7909808B2 (en) 2003-06-13 2011-03-22 Medlogic Global Limited Dual-ended applicator for dispensing two fluids
US20050019418A1 (en) 2003-07-23 2005-01-27 Crutchfield Charles E. Wart treatment
US20070111954A1 (en) 2003-07-23 2007-05-17 Cuticeuticals, Inc. Apparatus and method of wart treatment
JP2005187330A (ja) 2003-12-24 2005-07-14 Lion Corp 歯牙貼布用製品及びゲル組成物の選定方法
FR2865360B1 (fr) 2004-01-22 2006-05-26 Oreal Applicateur comportant un element d'application solidaire, lors de l'utilisation, d'un recipient contenant un produit a appliquer
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20050111900A1 (en) 2004-11-30 2005-05-26 Francesca Fazzolari Ampoule and method of use
FR2885779B1 (fr) 2005-05-23 2007-08-10 Oreal Dispositif de conditionnement et d'application d'un produit cosmetique ou dermatologique
US20070187437A1 (en) 2006-02-10 2007-08-16 Nordson Corporation Dispensing tip for liquid dispensing systems and method of making the same
US20070275045A1 (en) * 2006-02-28 2007-11-29 Evans Robin D Composition for the treatment of warts and molluscum contagiosum
JP5132071B2 (ja) 2006-03-31 2013-01-30 小林製薬株式会社 皮膚外用剤
DE102006034272A1 (de) 2006-07-18 2008-01-24 Aesculap Ag & Co. Kg Flüssigkeitsspender in der Medizin in Form einer Handhabe sowie dessen Verwendung
CN100465176C (zh) 2006-08-18 2009-03-04 芜湖天远科技开发有限责任公司 一种提取斑蝥素的方法
US20080146674A1 (en) 2006-12-15 2008-06-19 Rosenberg E William Use of gentian violet in treatment of atopic dermatitis
US8518076B2 (en) 2007-01-08 2013-08-27 Advanced Medical Solutions (Plymouth) Limited Surgical adhesive applicator
JP5230023B2 (ja) 2007-01-25 2013-07-10 ハイパーブランチ メディカル テクノロジー， インコーポレイテッド 複数成分製剤などのための塗布器および使用方法
CN100545164C (zh) 2007-02-13 2009-09-30 北京世纪博康医药科技有限公司 斑蝥酸钠的制备工艺
KR101329489B1 (ko) 2007-04-04 2013-11-13 엘지전자 주식회사 냉장고용 홈바
CN101036774B (zh) 2007-04-17 2010-12-29 贵州益佰制药股份有限公司 一种复方斑蝥口服制剂的检测方法
CN101108853B (zh) 2007-07-27 2010-05-26 贵州大学 斑蝥素分离纯化方法
CN101108854B (zh) 2007-07-27 2010-05-26 贵州大学 一种斑蝥素分离纯化方法
DE102007046600A1 (de) 2007-09-27 2009-04-02 Linhardt Metallwarenfabrik Gmbh & Co Kg Verfahren zum Applizieren eines flüssigen, medizinischen Behandlungsmediums auf einen zu behandelden Bereich sowie Medizinprodukt
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010079513A2 (en) * 2009-01-07 2010-07-15 Sanjay Banerji Painless treatment of warts, corns & callus
US9480691B1 (en) 2009-01-20 2016-11-01 Hill Dermaceuticals, Inc. Topical liquid containing refined peanut oil for treating skin proliferation or inflammation disorders
JP5396125B2 (ja) 2009-03-30 2014-01-22 有限会社日本健康科学研究センター 被膜形成型製剤
CN102573816A (zh) 2009-10-08 2012-07-11 Msd消费保健品公司 低醚组合物及输送装置
CN101798309A (zh) 2009-12-04 2010-08-11 南京泽朗医药科技有限公司 一种从斑蝥中制备斑蝥素的方法
US20120016320A1 (en) 2010-07-13 2012-01-19 Lin Michael T Method and Device for Liquid Delivery
US20120148520A1 (en) 2010-12-10 2012-06-14 Michael Strobel Organic Iodine Complex Durable Barrier With Antimicrobial Preparations
FR2972928B1 (fr) 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
US20120312709A1 (en) 2011-04-12 2012-12-13 Velcera, Inc. Device for storing and dispensing a medicament, and packaging for containing the same
CN102146086B (zh) 2011-04-12 2012-03-07 贵州金桥药业有限公司 一种斑蝥酸钠的制备方法
US9486829B2 (en) 2011-06-04 2016-11-08 Optmed, Inc. Applicator
CN102268006B (zh) 2011-06-15 2013-08-14 北京联合大学生物化学工程学院 一种复合酶提取斑蝥素的方法
US8871801B2 (en) * 2011-08-01 2014-10-28 Jacob LEVITT Method of treating acquired perforating dermatosis with cantharidin
CN102336765A (zh) 2011-10-11 2012-02-01 江苏四环生物股份有限公司 从斑蝥中提取斑蝥素的方法
CN102526146B (zh) 2012-01-13 2014-02-26 苏州大学 含有人参皂苷和斑蝥素的药物组合物及其用途
CN202730045U (zh) 2012-08-13 2013-02-13 遵义医学院 一种斑蝥素分离纯化的装置
CN202920809U (zh) 2012-09-27 2013-05-08 合肥诚者成医药科技有限公司 一种治疗尖锐湿疣的软膏
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
AU2014308690B2 (en) * 2013-08-21 2019-07-18 Verrica Pharmaceuticals, Inc. Compositions, methods and systems for the treatment of cutaneous disorders
US9994584B2 (en) 2014-10-15 2018-06-12 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
CA2971279C (en) 2014-12-17 2023-09-19 Matthew Davidson Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
US11168091B2 (en) 2015-01-20 2021-11-09 Verrica Pharmaceuticals Inc. Quantification and preparation of pharmaceutical grade cantharidin
EP3258908A4 (en) * 2015-02-20 2018-08-22 Pedicis Research LLC Compositions and methods for treatment of skin infections
USD771250S1 (en) 2015-12-22 2016-11-08 Adhezion Biomedical, Llc Liquid dispenser with an extended tip
USD772407S1 (en) 2015-12-22 2016-11-22 Adhezion Biomedical, Llc Liquid dispenser having a tapered tip
JP6903062B2 (ja) 2016-01-25 2021-07-14 ポレックス コーポレーション 複数要素の焼結多孔質液体アプリケータニブ
USD801830S1 (en) 2016-05-19 2017-11-07 Adhezion Biomedical, Llc Liquid dispenser
IL270900B1 (en) 2017-06-06 2024-08-01 Verrica Pharmaceuticals Inc Treatment of skin disorders
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
JP7497980B2 (ja) 2017-06-15 2024-06-11 ヴェリカ ファーマシューティカルズ インコーポレーテッド 体表面の障害の処置のためのデバイスおよび方法
ES2977612T3 (es) 2017-10-04 2024-08-27 Verrica Pharmaceuticals Inc Síntesis de cantaridina
USD868160S1 (en) 2018-03-26 2019-11-26 Robert Lam Multi-nib marker

Also Published As

Publication number Publication date
KR20200050941A (ko) 2020-05-12
MX2022008203A (es) 2022-08-04
IL270900A (en) 2020-01-30
IL314274A (en) 2024-09-01
CN111278414A (zh) 2020-06-12
JP2023061951A (ja) 2023-05-02
WO2018226894A1 (en) 2018-12-13
US20200155498A1 (en) 2020-05-21
IL270900B1 (en) 2024-08-01
AU2024204696A1 (en) 2024-07-25
US20210401793A1 (en) 2021-12-30
BR112019025625A2 (pt) 2020-06-16
JP7280870B2 (ja) 2023-05-24
US11147790B2 (en) 2021-10-19
EP3634370A4 (en) 2021-03-03
CA3065151A1 (en) 2018-12-13
AU2018281313B2 (en) 2024-05-02
WO2018226894A8 (en) 2019-01-31
JP2020522578A (ja) 2020-07-30
AU2018281313A1 (en) 2019-12-19
EP3634370A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
MX2022008203A (es) Tratamiento de trastornos cutaneos.
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017013983A (es) Uso de agentes activos durante tratamientos quimicos.
PH12018502634A1 (en) Topical compositions of apremilast
CA3081755A1 (en) Therapeutic cannabinoid formulations and methods for their use
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EP4140487A8 (en) Combination therapy for treating cancer
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX366502B (es) Composiciones y métodos para tratar heridas superficiales.
WO2016043874A3 (en) Combination therapy for treating cancer
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
MX2015010139A (es) Composicion antiseptica oral para tratamiento de mucositis oral.
PH12019501469A1 (en) Compositions and methods for treating biofilms
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
WO2018094023A3 (en) Cyclic dipeptides and wound healing
NZ706185A (en) Decubitus treatment system
MX2019011951A (es) Secretoma bacteriano para usarse en el tratamiento contra lesiones cutaneas.
EP2926867B1 (en) Peeling compositions comprising trichloroacetic acid (tca) and phenol for reducing the burning pain caused by the tca peeling
TR201619953A2 (tr) Topi̇kal terapöti̇k formülasyonlar